Fecal MMP-9: A New Noninvasive Differential Diagnostic and Activity Marker in Ulcerative Colitis
暂无分享,去创建一个
K. Farkas | F. Nagy | T. Wittmann | T. Molnár | V. Théodorou | I. Földesi | L. Buéno | O. Inczefi | L. Ferrier | A. Rosztóczy | F. Izbéki | R. Róka | K. Gecse | M. Szűcs | M. Dabek | A. Annaházi
[1] T. Wittmann,et al. Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. , 2009, The American journal of pathology.
[2] A. Zinsmeister,et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] D. Zurakowski,et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[4] D. Zurakowski,et al. Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy , 2008, Clinical Cancer Research.
[5] A. Schoepfer,et al. Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies , 2008, Inflammatory bowel diseases.
[6] S. Targan,et al. Recent understanding of IBD pathogenesis: Implications for future therapies , 2006, Inflammatory bowel diseases.
[7] P. Rutgeerts,et al. Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.
[8] M. Rojas,et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. , 2005, Gastroenterology.
[9] Li Yan,et al. The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients , 2005, Clinical Cancer Research.
[10] D. Gaya,et al. Faecal calprotectin in the assessment of Crohn's disease activity. , 2005, QJM : monthly journal of the Association of Physicians.
[11] C. N. Coleman,et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Bellini,et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[13] A. Poullis,et al. Emerging role of calprotectin in gastroenterology , 2003, Journal of gastroenterology and hepatology.
[14] A. Poullis,et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders , 2002, European journal of gastroenterology & hepatology.
[15] S. Walsh,et al. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. , 2001, The American journal of pathology.
[16] P. E. Van den Steen,et al. Gelatinase B: a tuner and amplifier of immune functions. , 2001, Trends in immunology.
[17] B. Thjódleifsson,et al. A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.
[18] C. J. Taylor,et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.
[19] A. Kossakowska,et al. Elevated Plasma Gelatinase A (MMP‐2) Activity Is Associated with Quiescent Crohn's Disease , 1999, Annals of the New York Academy of Sciences.
[20] M A Moses,et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. , 1998, Cancer research.
[21] T. Tsuruo,et al. Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. , 1993, Cancer research.
[22] A. Røseth,et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.
[23] M. Pepys,et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. , 1986, Gut.
[24] B. Shine,et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. , 1985, Clinica chimica acta; international journal of clinical chemistry.
[25] H. Hodgson,et al. Granulocyte migration in ulcerative colitis , 1985, European journal of clinical investigation.
[26] B. Molnár,et al. The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis , 2011, Pathology & Oncology Research.
[27] J. Jahnsen,et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.